The research team, led by Xuetong Zhu and Jiancheng Xu of the First Hospital of Jilin University in Changchun, China, together with colleagues from several Jilin institutions, assembled an unusually large immunological dataset. The analysis included 112 peripheral blood mononuclear cell samples, which allowed the investigators to probe T-cell responses, and 3,202 serum samples, which provided the statistical power needed to characterize antibody profiles across health and disease states. Using enzyme-linked immunosorbent assay to quantify antibody titers and enzyme-linked immunospot assay to measure cellular reactivity, the researchers built a two-pronged picture of what remains of vaccinia-induced immunity years after the last dose was administered.

The cellular arm of the study delivered a sobering message. Among individuals with historical smallpox vaccination, T-cell responses were limited, and — perhaps most strikingly — no significant differences were observed between healthy participants and those living with disease. In other words, the cellular memory that once formed a critical line of defense against variola virus and its relatives has thinned to a low, relatively flat baseline across the population studied. This matters because cell-mediated immunity is generally considered the more durable component of protection against orthopoxviruses, and its scarcity in previously vaccinated adults suggests that historical vaccination status alone cannot be assumed to confer meaningful cellular protection today.

The humoral picture was more nuanced and more clinically revealing. Vaccinated individuals with comorbidities had significantly lower immunoglobulin G titers against the vaccinia virus Tianan strain than their healthy counterparts, a difference that reached strong statistical significance with P values below 0.001. When the researchers broke the disease groups down into chronic disease subgroups, the variations persisted, indicating that the erosion of antibody memory is not a uniform process but one shaped by the specific burden of illness a person carries. Antibody titers are the standard surrogate for neutralizing capacity against orthopoxviruses, so lower titers in comorbid groups translate directly into a plausible reduction in protective buffering.

Regression analyses sharpened the risk stratification. Chronic disease was associated with lower odds of high antibody positivity, with an odds ratio of 0.67 and a 95 percent confidence interval of 0.44 to 0.98. Cancer carried an even stronger signal, with an odds ratio of 0.58 and a confidence interval of 0.37 to 0.90. These figures suggest that people with cancer who were vaccinated decades ago are roughly 40 percent less likely to maintain high-level antibody positivity than comparable healthy individuals. At the same time, the proportion of individuals with negative neutralizing antibody responses decreased with age — consistent with more of the oldest cohort having been vaccinated — but remained higher among disease groups than among healthy participants at every comparison point.

Beyond clinical diagnoses, the study uncovered associations between routine laboratory markers and antibody levels, offering a biochemical window into why some vaccinated individuals retain stronger humoral memory than others. High-density lipoprotein cholesterol, often called good cholesterol, showed a positive association with antibody levels, as did aspartate aminotransferase, an enzyme commonly monitored as a marker of liver and cellular turnover. Cholinesterase, by contrast, displayed an inverse association with antibody titers. While such correlations do not establish causation, they hint that metabolic and hepatic status may modulate the persistence of vaccine-induced humoral immunity, and they raise the possibility that routinely collected blood chemistry could help clinicians estimate residual orthopoxvirus protection without specialized immunological testing.

The second half of the study moved from measurement to simulation. The team constructed an exploratory susceptible-infected-recovered-dead model — a classic epidemiological framework that tracks individuals through states of susceptibility, infection, recovery, and death — parameterized with published epidemiological values rather than observed outbreak data. Within this framework, they simulated hypothetical transmission scenarios among immunocompromised populations to explore how reduced immune competence might alter the shape of an orthopoxvirus outbreak. The authors are careful to frame this modeling as exploratory and hypothetical, but the exercise provides a structured way to think about vulnerability that cannot ethically or practically be studied in real outbreaks.

The simulated scenarios produced an age-stratified pattern that public health planners will recognize as a double burden. In the model, immunocompromised individuals aged 15 to 19 years showed higher simulated infection proportions, suggesting that younger immunocompromised people — many of whom were never vaccinated and may have weakened immune systems due to disease or treatment — could contribute disproportionately to transmission in a hypothetical outbreak. At the other end of the age spectrum, individuals aged 70 and above showed higher simulated mortality proportions, reflecting the compounding of advanced age, waning or absent immunity, and reduced physiological reserve. Together, the two ends of the simulated curve sketch a scenario in which an orthopoxvirus introduction could simultaneously stress pediatric and adolescent transmission control and geriatric intensive care capacity.

The authors conclude that individuals with historical smallpox vaccination do show detectable residual immune responses, but that these responses vary meaningfully across comorbidity groups and correlate with measurable laboratory markers. They further suggest that immunocompromised individuals may warrant further evaluation for potential orthopoxvirus susceptibility — a recommendation that carries practical weight given that mpox clade outbreaks continue to evolve and that smallpox vaccines, including modern non-replicating formulations, are being redeployed in some settings. The study does not claim that previously vaccinated people are unprotected, nor does it establish that the modeled outbreak dynamics would occur in reality; its value lies in quantifying the heterogeneity of residual immunity and in providing a transparent, parameterized starting point for preparedness planning.

What emerges from the combined evidence is a portrait of a partially protected world. The generation vaccinated before routine smallpox immunization ended carries measurable but uneven antibody memory, eroded most in those with chronic disease and cancer, and supported by cellular responses too limited to distinguish the sick from the healthy. Meanwhile, younger immunocompromised people who never received the vaccine represent a structurally susceptible population in whom simulated outbreaks spread more readily. As the authors note, these findings may inform future orthopoxvirus preparedness and prevention strategies — from targeted serological screening of comorbid vaccinees to prioritized vaccination of immunocompromised cohorts — and they underscore a broader lesson of post-eradication immunology: population immunity is not a switch that stays on, but a gradient that shifts with age, health, and time.

Subject of Research: Residual smallpox vaccine immunity and orthopoxvirus outbreak modeling in immunocompromised populations

Article Title: Residual immune responses after historical smallpox vaccination and exploratory outbreak modeling in immunocompromised populations

Article References: Zhu, X., Wang, J., Wang, X., Tu, Z., Zhou, Q., Zhu, Y., & Xu, J. (2026). Residual immune responses after historical smallpox vaccination and exploratory outbreak modeling in immunocompromised populations. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08907-3

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08907-3

Keywords: smallpox vaccination, orthopoxvirus, mpox, neutralizing antibodies, immunocompromised, vaccinia virus, humoral immunity, cellular immunity, SIRD model, antibody titers, chronic disease, outbreak modeling